Literature DB >> 31882553

BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.

Taku Tsukamoto1, Shingo Nakahata2, Ryuichi Sato3, Akinori Kanai4, Masakazu Nakano3, Yoshiaki Chinen1, Saori Maegawa-Matsui1, Yayoi Matsumura-Kimoto1, Tomoko Takimoto-Shimomura1, Yoshimi Mizuno1, Saeko Kuwahara-Ota1, Yuka Kawaji1, Masafumi Taniwaki1,5, Toshiya Inaba4, Kei Tashiro3, Kazuhiro Morishita2, Junya Kuroda6.   

Abstract

BACKGROUND: Since bromodomain-containing protein 4 (BRD4) facilitates the transcription of genes important for neoplastic cells in a cancer-type specific manner, BRD4-regulated molecules may also include therapeutic targets for mantle cell lymphoma (MCL), a treatment-refractory subtype of malignant lymphoma.
MATERIALS AND METHODS: In order to uncover direct BRD4-regulated targets in MCL, we performed integrated analysis using the pathway database and the results of both gene-expression profiling and chromatin immunoprecipitation with parallel sequencing for BRD4.
RESULTS: Treatment with BRD4 inhibitor I-BET151 exerted a dose-dependent inhibitory effect on cell proliferation in MCL cell lines. BRD4 was found to directly regulate series of genes involved in the B-cell receptor (BCR) signaling pathway, including B-cell linker (BLNK), paired box 5 (PAX5), and IKAROS family zinc finger 3 (IKZF3), and several oncogenes, such as MYB. Indeed, the combinatory inhibition of BCR pathway and IKZF showed an additive antitumor effect.
CONCLUSION: Concomitant targeting multiple BRD4-regulated molecules may constitute a rational therapeutic strategy for MCL. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  BRD4; ChIP-Seq; Mantle cell lymphoma; drug resistance; super-enhancer

Mesh:

Substances:

Year:  2020        PMID: 31882553      PMCID: PMC6937128          DOI: 10.21873/cgp.20169

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  33 in total

1.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Richard I Fisher; Steven H Bernstein; Brad S Kahl; Benjamin Djulbegovic; Michael J Robertson; Sven de Vos; Elliot Epner; Amrita Krishnan; John P Leonard; Sagar Lonial; Edward A Stadtmauer; Owen A O'Connor; Hongliang Shi; Anthony L Boral; André Goy
Journal:  J Clin Oncol       Date:  2006-09-25       Impact factor: 44.544

3.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Authors:  Camilla L Christensen; Nicholas Kwiatkowski; Brian J Abraham; Julian Carretero; Fatima Al-Shahrour; Tinghu Zhang; Edmond Chipumuro; Grit S Herter-Sprie; Esra A Akbay; Abigail Altabef; Jianming Zhang; Takeshi Shimamura; Marzia Capelletti; Jakob B Reibel; Jillian D Cavanaugh; Peng Gao; Yan Liu; Signe R Michaelsen; Hans S Poulsen; Amir R Aref; David A Barbie; James E Bradner; Rani E George; Nathanael S Gray; Richard A Young; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

4.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

5.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

6.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

7.  Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.

Authors:  Regina Wan Ju Wong; Phuong Cao Thi Ngoc; Wei Zhong Leong; Alice Wei Yee Yam; Tinghu Zhang; Kaori Asamitsu; Shinsuke Iida; Takashi Okamoto; Ryuzo Ueda; Nathanael S Gray; Takashi Ishida; Takaomi Sanda
Journal:  Blood       Date:  2017-10-04       Impact factor: 22.113

8.  Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.

Authors:  Tomoko Takimoto-Shimomura; Taku Tsukamoto; Saori Maegawa; Yuto Fujibayashi; Yayoi Matsumura-Kimoto; Yoshimi Mizuno; Yoshiaki Chinen; Yuji Shimura; Shinsuke Mizutani; Shigeo Horiike; Masafumi Taniwaki; Tsutomu Kobayashi; Junya Kuroda
Journal:  Invest New Drugs       Date:  2018-06-21       Impact factor: 3.850

9.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

10.  Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.

Authors:  A E Teo; Z Chen; R N Miranda; T McDonnell; L J Medeiros; N McCarty
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

View more
  2 in total

1.  EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.

Authors:  Daichi Nishiyama; Yoshiaki Chinen; Reiko Isa; Yuto Fujibayashi; Saeko Kuwahara-Ota; Junko Yamaguchi; Tomoko Takimoto-Shimomura; Yayoi Matsumura-Kimoto; Taku Tsukamoto; Yuji Shimura; Tsutomu Kobayashi; Shigeo Horiike; Masafumi Taniwaki; Hiroshi Handa; Junya Kuroda
Journal:  Int J Hematol       Date:  2020-10-23       Impact factor: 2.490

Review 2.  Ikaros Proteins in Tumor: Current Perspectives and New Developments.

Authors:  Ruolan Xia; Yuan Cheng; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  Front Mol Biosci       Date:  2021-12-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.